

Supporting Information

TITLE: A focused screen identifies antifolates with activity on *Mycobacterium tuberculosis*

AUTHORS: Anuradha Kumar¹, Ana Guardia², Gonzalo Colmenarejo³, Esther Pérez², Ruben Gonzalez², Pedro Torres², David Calvo², Ruben M. Gómez², Fátima Ortega², Elena Jiménez², Raquel Gabarro², Joaquín Rullás², Lluís Ballell², David R. Sherman^{1,4}

This supporting information file contains two tables (Table S1 and Table S2) and one figure (Figure S1) and is two pages in length.

A. DQn-1 *in vivo* DMPK study

The *in vivo* DMPK profile of DQn-1 was evaluated in mice as described in the methods section of the manuscript. The results are shown in Figure S1 and Table S1.

Figure S1. *In vivo* DMPK results from administration of DQn-1 at 5 and 500 mg/kg




Figure S1: *In vivo* DMPK study with DQn-1. Data obtained from mice when DQn-1 was administered orally (p.o.) at 5 and 500 mg/kg.

Table S1: Results of *in vivo* DMPK study with DQn-1.

Data from the pharmacokinetic studies performed on CD1 male mice (n=3) at two doses of compound administered by oral route (p.o.). The mean and standard deviation (SD) values are shown for the area under the curve (AUC_{last}) and the $AUC/dose$ ($DNAUC_{last}$) at the last time point measured (T_{last}), the time point when highest dose was reached (T_{max}), the highest concentration reached


(C_{max}), and the maximum observed amount of compound/dose administered (C_{max}/dose).

Table S1: Results of *in vivo* DMPK study with DQn-1

Route (dose)		AUC _{last} (ng*h/mL)	T _{last} (h)	DNAUC _{last} (ng*h/mL per mg/kg)	T _{max} (h)	C _{max} (ng/mL)	C _{max} /dose (ng/mL per mg/kg)
p.o. (5 mg/kg)	Mean	1310	48	261	0.9	189	37
	SD	494	0	99	0.1	100	20
p.o. (500 mg/kg)	Mean	19900	40	40	2.7	2000	4
	SD	6380	14	13	1.2	771	2

B. DQn-1 *in-vivo* efficacy study

Figure S2: Outcomes of *in vivo* efficacy study with DQn-1.



Mtb infected mice were administered DQn-1 by oral route (po) at 5 and 10 mg/kg for 8 days and sacrificed on day 9. The results did not reveal any significant reduction of Mtb burden after treatment with DQn-1 compared with untreated mice. As a positive control, five mice treated with 30 mg/kg moxifloxacin showed more than a 2 log reduction in colony forming units (CFU) harvested from the lungs.